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Abstract
Introduction Despite extensive research, anastomotic leakage
(AL) remains one of the most dreaded complications after
colorectal surgery. Since butyrate enemas are known to en-
hance anastomotic healing, several administration routes have
been explored in this study.
Methods Three intraluminal approaches involving butyrate
were investigated: (1) butyrin-elucidating patch, (2) a single
injection of hyaluronan-butyrate (HA-But) prior to construc-
tion of the proximal anastomosis and (3) rectal hyaluronan-
butyrate (HA-But) enemas designed for distal anastomoses.
The main outcome was AL and secondary outcomes were
bursting pressure, histological analysis of the anastomosis,
zymography to detect MMP activity and qPCR for gene ex-
pression of MMP2, MMP9, MUC2 and TFF3.
Results Neither the patches nor the injections led to a reduc-
tion of AL in experiments 1 and 2. In experiment 3, a signif-
icant reduction of AL was accomplished with the (HA-But)
enema compared to the control group together with a higher
bursting pressure. Histological analysis detected only an in-
creased inflammation in experiment 2 in the hyaluronan injec-
tion group compared to the control group. No other differ-
ences were found regarding wound healing. Zymography
identified a decreased proenzyme of MMP9 when HA-But
was administered as a rectal enema. qPCR did not show any
significant differences between groups in any experiment.
Conclusion Butyrate enemas are effective in the enhancement
of colonic anastomosis. Enhanced butyrate-based approaches
designed to reduce AL in animal models for both proximal
and distal anastomoses were not more effective than were
butyrate enemas alone. Further research should focus on
how exogenous butyrate can improve anastomotic healing
after gastrointestinal surgery.
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Introduction
Despite extensive research, anastomotic leakage (AL) remains
one of the most dreaded complications after colorectal sur-
gery. It still results in high morbidity and mortality, and causes
prolonged hospital stay and high healthcare costs [1–3]. Many
studies have been performed regarding this subject, all aiming
at improvement of anastomotic healing and thereby
preventing leakage. Since the incidence of anastomotic leak-
age has not declined over the years, the need for a solution
continues to exist [4, 5].
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Previous animal studies have shown that rectal administra-
tion of butyrate—one of the predominant short chain fatty
acids (SCFAs)—results in a higher bursting pressure in colon-
ic anastomoses, thereby claiming an enhanced strength which
may prevent anastomotic leakage [6–8].
These positive results did not change current practice, nor
have human studies been reported in which patients received
postoperative butyrate enemas to enhance anastomotic strength.
This is not surprising, when you consider that clinicians are not
keen on enemas directly after surgery, especially when a fragile
rectal anastomosis is involved. Water-soluble contrast enemas
are often used to determine the presence of colorectal AL,mostly
after rectum resection. However, these enemas are never given in
the very early postoperative phase (<postoperative day 5) due to
the potential risk of complications [5]. Another disadvantage of
the use of enemas is the low compliance rate and the short and
discontinuous exposure of butyrate to the colonic mucosa.
A recent study however showed that butyrate has remarkable
anti-inflammatory and regenerative effects improving the repair
of intestinal mucosa in rats with colitis [9]. Butyrate stimulates
re-epithelisation and may influence collagen lysis by reducing
matrixmetalloproteinase (MMP) release [10]. Butyrate is a prod-
uct of the fermentation process by bacteria that occurs mainly in
the distal colon. Because it serves as the most important energy
source for colonocytes [11], our hypothesis is that increasing the
concentration of butyrate will lead to an enhanced anastomotic
healing in the colon. A number of studies indicate that butyrate
affects the composition and thickness of the colonic mucus layer
through alteration of mucin gene expression [12] and nutritional
deficiency of the colonic epithelium and that butyrate also can
act as a signalling molecule through specific G-protein-coupled
receptors that are involved in the immune surveillance of the
colonic mucosa towards microbial activity [13]. More recently,
it has been shown that mice with an insufficient mucus layer on
the colonic mucosa (Muc2−/−) suffered more often from anasto-
motic leakage compared to control mice [14].
Furthermore, animal studies showed that butyrate enemas
have a significant positive effect on the left colonic anastomo-
ses, but this effect was weaker on the right side of the colon [8].
Obviously, not the same volume will reach the proximal anas-
tomotic site compared to the distal anastomosis, which may
explain these findings. Another explanation might be that the
butyrate-producing bacteria mainly reside in the mucus layer at
the distal part of the colon, that the proximal colon does not
respond to a higher amount of butyrate, simply because the
proximal enterocytes are not familiar to having that energy
source available and are not able to use it. To increase the
beneficial effect of butyrate, we added hyaluronan (HA), a gly-
cosaminoglycan that is known to promote neovascularization,
to enhance the process of scarring, and it has beneficial effects
on cell proliferation in several tissues [15, 16]. Hyaluronan also
plays a role in the downregulation of the inflammatory re-
sponse. Its free-radical scavenging and antioxidant properties
and its supposed inhibiting effect on proteinases such as MMPs
seem to be responsible for this downregulation, stabilizing the
granulation tissue during the healing process [16].
In this study, we investigated several ways to improve the
proximal anastomotic strength by applying butyrate near this
anastomosis: using a patch, injections and enemas. Our aim
was to develop a method that resulted in a lower anastomotic
leakage rate and more practical methods that can be applied in
daily clinical practice.
Methods
Animals
Eighty-four Wistar rats with a body weight of 250–300 g were
used. Animals were housed and cared for at the Central
Animal Facility of Maastricht University. All animals were
provided ad libitum access to food and water and were cared
for according to local standards. Postoperatively, welfare as-
sessment was performed twice daily using a standardized
method and animals were given pain medication in case of
discomfort. The experimental protocol complied with the
Dutch Animal Experimental Act and was approved by the
Animal Experimental Committee of Maastricht University
Medical Center. The ARRIVE guidelines for reporting
in vivo experiments were followed [17] (see also
supplementary data S1).
Study design
Primary objective of the study is to investigate if anastomotic
leakage can be reduced in a leakage model by application of
either an intraluminal butyrin-eluting patch, a single-time
intraluminal administration of butyrate or a daily HA-But en-
ema. For the proximal anastomoses, we used both an
intraluminal butyrin-eluting patch that covered the anastomo-
sis and a single-time intraluminal administration of
hyaluronan-butyrate (HA-But). Since most research is per-
formed in the distal part of the colon, we also used a left-
colon anastomosis model to test the HA-But enemas. This
resulted in the following three experiments:
Experiment 1: Butyrin-eluting patches (20massa% tributyrin)
versus placebo patches (n = 12/group)
Experiment 2: HA-But injection (5% HA, 60 mM butyrate)
versus HA injection (5% HA) versus saline
injection (0.9% NaCl) (n = 8/group)
Experiment 3: Five millilitres of HA-But enema (5% HA,
60 mM butyrate) versus 5 mL sodium buty-
rate (60 mM) enema versus a control group
that received no enemas (n = 12/group)
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Patches were kindly provided by Polyganics (Groningen,
the Netherlands), and enemas and injections were produced
by Sigea (Trieste, Italy).
In all experiments, follow up was 7 days.
Surgical procedure
All rats received 0.05 mg/kg buprenorphine as analgesic and
were anaesthetised using isoflurane. To acquire access to the
abdominal cavity, a 5-cm craniocaudal midline incision of the
skin and abdominal musculature was made in all experiments.
The cecum was then identified and moved outside of the peri-
toneal cavity and onto sterile gauzes that were hydrated with
sterile saline solution to prevent dehydration. For proximal
anastomoses, the colon was transected two centimetres distal
from the cecum and an end-to-end anastomosis was created
using four interrupted polypropylene 6/0 sutures (Prolene,
Ethicon, Johnson & Johnson) (Exp 1& 2, see supplementary
data S1). In experiment 3, the anastomosis was performed in
similar fashion but at 4 cm ab ani. After performing the anas-
tomosis, the intestines were repositioned and the abdomen
was closed in two layers, a running suture for the muscle layer
(Vicryl 4-0, Ethicon, Inc) and interrupted sutures for the skin
(Monocryl 4-0, Ethicon, Inc).
Macroscopic endpoints
Anastomotic leakage was defined as (1) no anastomotic leak-
age, (2) small abscess at the anastomotic site <1cm3, (3) large
(>1cm3) abscess at the anastomotic site or (4) complete dehis-
cence with peritonitis/death due to faecal peritonitis.
Adhesions to the anastomotic site were assessed according
to van der Ham et al. [18]
Bursting pressure
Bursting pressure was measured as previously described [19].
In short, a 5-cm segment of intestine including the anastomo-
sis with adherent organs was resected en bloc and the part
distal of the anastomosis was clamped. A plastic tube was
inserted in the proximal end and ligated with a single
polyglactine 4/0 suture (Vicryl, Ethicon). The complete anas-
tomosis was immersed in phosphate-buffered saline, while air
was infused using a manometer (IDEE, Maastricht University,
the Netherlands) and pressure was manually increased by in-
flating the colon. Bursting pressure was defined as the
intraluminal pressure at which air leakage was initially ob-
served from the anastomosis (mBar).
Tissue preparation
In anaesthetised rats, the anastomotic site was dissected (after
measuring bursting pressure) with a 0.5-cmmargin at each site
of the anastomosis. Tissue samples were divided in three equal
pieces: one for qPCR, one for zymography purposes and one
for immunohistochemistry purposes. This latter one was cut in
longitudinal direction and tissue was stretched and pinned
onto a cork layer in order to secure a straight anastomotic line
and improve quality of histological assessment prior to fixa-
tion in formalin (supplementary data S2). Sections were
deparaffinized in xylene and rehydrated in graded ethanol to
distilled water prior to performing histological staining. The
part dedicated for qPCR analysis was snap frozen in liquid
nitrogen and stored at −80 °C until required for mRNA
isolation.
Histology and immunohistochemistry
Sections were stained with standard haematoxylin-eosin and
Picro Sirius Red using Direct Red 80 and Picric Acid solution
(both Sigma-Aldrich, the Netherlands).
An independent, experienced animal pathologist per-
formed blinded histological assessment on the obtained tissue,
scoring (from 0 to 4) histological sections on inflammation,
granulocyte influx, fibroblast activity and collagen deposition.
Collagen ration was calculated using an in-house software
program on pictures obtained with a polarized light micro-
scope (Leica DM5000B, Leica Microsystems, Wetzlar,
Germany).
MMP2, pro-MMP9 and MMP9 activity analysis using
zymography
MMP2 and MMP9 activities were assessed using gelatin
zymography since its increase of MMP activity has been im-
plicated in the pathogenesis of AL [20]. Samples were lysed
from tissue and loaded on a polyacrylamide gel containing
gelatin (10% Ready Zymogram Gel, Bio-Rad, the
Netherlands). Gel electrophoresis took place at 100 V for
30 min. After that, the gel was incubated with 2.5% Triton
X-100 in MQ for 30 min at room temperature. The gel was
then placed in developing buffer at 37 °C overnight.
Colouring of the gel took place the following night with
PAGE-Blue protein staining solution (Thermo Scientific, the
Netherlands). At day 3, the staining was decoloured with MQ,
revealing MMP2 and MMP9 activity. The gels were scanned
using a Bio-Rad GS-800 Densitometer and digital quantifica-
tion was done using ImageJ software (ImageJ Software, U.S.
National Institutes of Health, Bethesda, Maryland, USA).
MMP2,MMP9, TFF3 andMuc2 expression analysis using
qPCR
The expression of matrix metalloproteinases 2 (MMP2) and 9
(MMP9) as well as mucin 2 (MUC2) and trefoil factor 3
(TFF3) was determined using qPCR to see if exogenous
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butyrate had an effect on the expression of these MMPs and
the abundant secretory mucin MUC2 as well as its associated
trefoil factor. All qPCR-experiments were carried out by a
dedicated technician (BB) and are reported as detailed as pos-
sible according to the MIQE guidelines [21]. RNAwas isolat-
ed from the tissue sample using TRI reagent (Sigma-Aldrich,
the Netherlands) and treated with RNase-Free DNase Set
(Qiagen). The purity of RNA was tested using Nanodrop
Spectrophotometer (Thermo Scientific) by 260/280 absor-
bance (A260/A280) ratios, ranging from 1.89 to 2.02.
Therefore, the purity of the isolated RNA was satisfactory
for further studies. RNA of 750 ng was converted to DNA
with sensifast cDNA Synthese kit (Bioline, London, UK).
qPCR was performed on 10 ng cDNA with 0.3 μM primers
in Sensimix SYBR & Fluorescein Kit (Bioline, London, UK)
using white 384-wells qPCR plate. Primer sequences are listed
in Table 1. Reference genes included were glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and B-actin. Reactions
were run on the LightCycler480 (Roche). PCR conditions
used were 10 min at 95 °C, followed by 40 amplification
cycles of 15 s at 95°-60 °C–72 °C followed by a melting curve
to validate the amplifications. The cycle threshold (Ct) value
of each reference gene was obtained from qPCR analysis. The
obtained Ct values were applied to evaluate the expression of
the genes of interest. The mean Ct value of the reference genes
ranged from 16 to 23 cycles, with HA-injection having the
highest transcript levels in MMP9, and butyrin patch was
associated with having the lowest transcript levels in TTF3.
For analysis purposes, the level of MMP2 expression of the
saline group was set at 1 and used as a control.
Statistical analyses
Statistical analysis was performed using Prism 5.0 for Mac
(Graphpad software, San Diego, CA). Normality was tested
using Kolmogorov-Smirnov. All continuous variables are pre-
sented as mean and standard error of the mean (SEM) and
compared using student’s t test or Mann Whitney U when
appropriate. Dichotomous variables were compared using
the Chi-square test.
Results
Macroscopical results
In experiment 1, two rats in the butyrin patch group died prior
to completing follow-up due to faecal peritonitis. All animals
in experiment 2 completed the 7-day follow up. In experiment
3, three rats (one in the HA-But group, three in the But group)
were euthanized because they had reached humane endpoints,
due to faecal peritonitis. An overview of the types of anasto-
motic leakage within each experimental group can be found in
Fig. 1a. Adhesions occurred in every experiment, and there
were no significant differences between experiments (proxi-
mal versus distal anastomoses) nor within each experiment
(Fig. 1b). It became evident that animals receiving a patch
(either butyrin eluting or placebo) had lower welfare scores
and significant more weight loss compared to animals receiv-
ing enemas (Fig. 1C), possibly due to an extended bowel
proximal to the location of the patch upon sacrifice.
Bursting pressure
Bursting pressure (BP) was not measured during experiment 1
because of evident extended intestines in the majority of the
rats at the place where the patches were placed. This abrupt
change in luminal calibre made the dilated bowel very porous,
disabling accurate BPmeasurements. In experiment 2, BPwas
measured and compared to a historical control group since the
control group from experiment 3 received a distal anastomo-
sis. No differences were found in experiment 2 between saline
injections, HA injections and HA-But injections. In experi-
ment 3, however, a significant difference could be found be-
tween the control group (104.1 ± 40.8) and HA-But
(250.7 ± 23.1) and But enemas (256.4 ± 44.4, p < 0.05).
Histology and collagen ratio
Inflammatory parameters were scored as a surrogate marker of
anastomotic healing, as indicated appropriately by a recent
Delphi consensus method [22]. Histological analysis (Fig. 2)
only detected an increased inflammation in experiment 2 in
the hyaluronan injection group (2.18 ± 0.22) compared to the
control group (3.27 ± 0.27, p < 0.05). No other differences
were found regarding wound healing. Picro Sirius red stain-
ing, which depicts the level of collagen maturity, of the anas-
tomotic region showed comparable percentages of collagen
for all groups (Table 2).
Table 1 Primer sequences used for qPCR experiments
r-MMP9-F1 AGCCGACGTCACTGTAACTG
r-MMP9-R1 AACAGGCTGTACCCTTGGTC
r-MMP2-F1 ACAACAGCTGTACCACCGAG
r-MMP2-R1 GGACATAGCAGTCTCTGGGC
R-MUC-F1 CGAAGTGAAGAGTGAGCACG
R-MUC-R1 GATCCGGGTGGTATTCAGCA
R-Tff-F1 GGCCTATCTCCAAGCCAATGT
R-Tff-R1 TGCAGAGGTTTGAAGCACCA
GAPDH FW GGAAGCTCACTGGCATGGC
GAPDH RV CCTGCTTCACCACCTTCTTG
Beta-actin FW GACAGGATGCAGAAGGAGATTACTG
Beta-actin RV CCACCGATCCACACAGAGTACTT
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Pro-MMP9, MMP2 and MMP9 activities measured
by zymography
Zymography revealed no differences between MMP2 and
MMP9 activity within each experiment between control and
intervention groups (Fig. 3). There was relatively large vari-
ability within the samples of each group as can be seen by the
error bars/whiskers in the different graphs. In experiment 3,
the addition of hyaluronan to the butyrate enema did decrease
the activity of pro-MMP9 (40.6 ± 8.2) compared to the buty-
rate enema alone (102.6 ± 26.9) and the control group
(114 ± 20.9, p = 0.01).
qPCR showed no significant differences in the three
experiments regarding gene expression
In experiment 1, a trend was found in the expression of MMP2
between the group that received a butyrin patch (0.35 ± 44.4)
Fig. 1 Butyrate-enriched enemas
reduced AL in Exp. 3, no other
butyrate-based intervention
caused a decrease in AL rates (a).
Adhesion scores did not differ
significantly between groups in
Exp. 1, 2 or 3 (b).Weight loss was
most prominent in Exp. 1 where
placement of the patches caused a
sudden change in calibre of the
colon; animals receiving enemas
had the lowest percentage of
weight loss but also received a
different type of anastomosis
compared to animals in Exp. 1
and 2 (distal vs proximal
respectively) (c). The
administration of butyrate enemas
caused a significant higher
bursting pressure of the
anastomosis in Exp. 3 compared
to the control group. No
differences were found in Exp. 2
and in Exp. 1; no BP was
measured due to porous,
distended intestines
Fig. 2 Histological analysis only detected an increased inflammation in experiment 2 in the hyaluronan injection group (2.18 ± 0.22) compared to the
control group (3.27 ± 0.27, p < 0.05). No other differences were found regarding wound healing. Values are mean ranking (S.E.M.)
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and the placebo patch group (1.14 ± 0.34, p < 0.07, Fig. 4). The
other tested matrix-metalloproteinase MMP9 also showed a
trend between these two groups, 0.39 ± 0.21 versus
1.14 ± 0.34 respectively, p < 0.08. No differences were found
regarding MUC2 and TFF3. In experiments 2 and 3, no signif-
icant differences were found in gene expression between the
intervention and control groups regarding all genes of interest.
Discussion
This study is the first study as far as we know that aims to
improve butyrate supplementation in animal models to over-
come the reservation of surgeons to optimize their patients
with butyrate prior or during gastrointestinal surgery. We in-
vestigated different administration routes besides enemas that
could enable surgeons to incorporate butyrate in the surgical
procedure. Unfortunately, a single dosage of butyrate or a
butyrin-eluting patch that we used in this study did not seem
promising. Addition of hyaluronan to butyrate did not im-
prove the effect of an enema on the healing of distal
anastomoses. Unfortunately, this study did not lead to prom-
ising tools to transport butyrate to the proximal anastomotic
site, but it did confirm that butyrate can lead to better anasto-
motic healing and this should be further investigated in the
future.
Butyrate is known to have a critical mediating role in the
colonic inflammatory response; for example, it can induce the
differentiation of colonic regulatory T cells and thereby ame-
liorate the development of colitis as shown by Furusawa et al.
[23]. More recently, it has been shown that exogenous buty-
rate restoration improved intestinal epithelial cell junctional
integrity, decreased apoptosis and mitigated graft-versus-
host-disease after allogeneic bone marrow transplant [24].
Especially the restorative effect of butyrate on the epithelial
integrity and, consequently, a decreased translocation of lumi-
nal contents are of great interest in the field of anastomotic
leakage. It was often assumed that butyrate increases collagen
synthesis and maturation and that this reduced the risk of
anastomotic leakage [6–8]; however, with these new insights,
it can be hypothesised that increased epithelial integrity leads
to a lesser amount of (clinically relevant) anastomotic leakage.
Fig. 3 Zymography revealed no differences between MMP2 and MMP9
activity within each experiment between control and intervention groups.
The addition of hyaluronan to the butyrate enema did decrease the activity
of pro-MMP9 (40.6 ± 8.2) compared to the butyrate enema alone
(102.6 ± 26.9) and the control group (114 ± 20.9) in experiment 3
(p = 0.01). Values are given in arbitrary units and data represent
mean + S.E.M.
Table 2 Total collagen and
mature/immature collagen ratios Experiment 1 Butyrin patch Placebo patch p value
Collagen percentage (%) 32.25 (±2.69) 28.64 (±2.00) 0.239
Red/green ratio 464.83 (±278.36) 361.42 (±207,96) 0.861
Experiment 2 Saline injection HA-But injection HA injection p value
Collagen percentage (%) 53.22 (±2.04) 45.29 (±4.51) 46,50 (±4.83) 0.361
Red/green ratio 66.89 (±16.76) 39.66 (±7.88) 95.64 (±44.43) 0.340
Experiment 3 Control HA-But enema Butyrate enema p value
Collagen percentage (%) 42.84 (± 4.75) 35.57 (± 4.23) 35.93 (± 2.12) 0.343
Red/green ratio 321.50 (±71.60) 282.00(±154.85) 176.54 (±46.35) 0.355
The relative collagen area was quantified as the percentage of total tissue surface. Maturity of collagen was
estimated by calculating the red/green ratio. Red indicates thick, mature collagen. Green indicates thin, immature
collagen In terms of collagen percentage and red/green ratio, no significant differences were found between
groups. All measurements in this table are presented as mean (±SEM)
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As stated before, enemas seem to be a promising tool
to deliver butyrate in the colon, especially in more distal
anastomoses; however, it remains difficult to reach the
same levels of butyrate in proximal anastomoses. In addi-
tion, butyrate is metabolized rapidly as soon as it enters
the colonocyte via its active transport system. This could
be the reason that experiment 2 was not successful; the
amount of available butyrate by a single injection was
simply not sufficient to cause any effect on the anasto-
motic site.
It was suggested that a prodrug of natural butyrate,
tributyrin, could overcome the pharmacokinetic drawbacks
of natural butyrate as a drug [25]. Since it was very difficult
to incorporate butyrate in an eluting patch, butyrin was used
instead, making sure that there were high concentrations avail-
able at the site of release. Unfortunately, the attachment of a
patch into the colon caused extension of the bowel proximal to
the location of the patch, indicating colonic stenosis. This
effect of patches or fleeces has been previously described
[26]; however, in that study, the authors used an external
fleece and in experiment 1, the film-like resorbable patches
were attached intraluminally. This stenosis effect—clinically
translatable to ileus—could be the explanation of why the
animals in experiment 1 had lower welfare scores and lower
weight compared to the other groups.
Hyaluronan is generally known to be associated with tissue
repair and wound healing, and its concentration is high in
healing tissues [27]. Its biological functions are the result of
both its physicochemical properties and its biological interac-
tions, depending onmolecular weight [28]. Despite the logical
hypothesis that the addition of hyaluronan to butyrate would
enhance anastomotic healing, this was not observed in this
study, possibly due to a low concentration or not having the
appropriate molecular weight.
One of the limitations of this study—even if the newly
tested approaches were successful—is the translation to
the human setting. While butyrate can be administered
as a rectal enema, this is rather invasive and not the pre-
ferred choice in drug administration. The risk of
anastomotic dehiscence in a recent constructed anastomo-
sis remains, which could be an explanation of the faecal
peritonitis that was found in the enema groups in experi-
ment 3. However, the very unpleasant odour and taste of
butyrate makes oral administration extremely difficult.
For this reason, Raso et al. have studied a derivative of
butyrate, N-(1-carbamoyl-2-phenyl-ethyl) butiramide
(FBA) as a successful therapeutic alternative to butyrate,
sharing a comparable efficacy, but a better palatability and
compliance, unfortunately so far only in a rat model [29].
Other articles that describe oral administration of butyrate
were also designed as animal s tudies [30, 31] .
Nevertheless, there are a few studies in which oral buty-
rate or its prodrug was given in humans and was consid-
ered safe and well tolerated [32]. The question remains if
butyrate can be administered as a local agent at the site of
the anastomosis, without potential harmful effects when it
enters the systemic circulation. Van Beek et al. have re-
cently demonstrated that splanchnic butyrate release was
prevented in patients after colonic butyrate administration,
indicating that rectal enemas even with high therapeutic
dosage (up to 100 mmol/L) of butyrate can be given safe-
ly [33].
Conceivably new approaches may become available as
nano-based drug delivery systems for encapsulation and
release of drugs are currently being investigated in differ-
ent fields of medicine [34, 35]. Imaginably in the future,
butyrate tablets will become standard perioperative treat-
ment and due to nanotechnology, the release of butyrate
will only take place at the site of interest, the colonic
anastomosis.
In conclusion, butyrate can enhance the colonic anas-
tomosis, making it less prone to lead to leakage. The most
effective method thus far is by rectal enemas and the
addition of hyaluronan did not ameliorate the effect of
butyrate on the AL rate. Further research should be done
to identify the optimal way of butyrate delivery to the
anastomotic site where it can enhance anastomotic
healing.
Fig. 4 Overview of relative gene expression where the level of MMP2 expression of the saline group was set at 1 and used as a control. No significant
differences were found in gene expression between the intervention and control groups regarding all genes of interest in the separate experiments
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